X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (817) 817
Publication (65) 65
Book Review (22) 22
Newsletter (12) 12
Book / eBook (5) 5
Book Chapter (5) 5
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (458) 458
animals (387) 387
index medicus (338) 338
male (318) 318
pharmacology & pharmacy (226) 226
female (204) 204
fatty acids, monounsaturated - pharmacokinetics (162) 162
rats (162) 162
fatty acids (161) 161
lipids (152) 152
fluvastatin (132) 132
mice (131) 131
adult (127) 127
metabolism (123) 123
fatty acids, monounsaturated - pharmacology (122) 122
monounsaturated fatty acids (115) 115
pharmacokinetics (111) 111
middle aged (99) 99
nutrition & dietetics (97) 97
biochemistry & molecular biology (91) 91
indoles - pharmacokinetics (89) 89
cholesterol (81) 81
diet (78) 78
research (75) 75
indoles - pharmacology (73) 73
research article (73) 73
analysis (71) 71
fatty acids, monounsaturated - chemistry (71) 71
drug interactions (67) 67
fatty acids, monounsaturated - administration & dosage (65) 65
fatty acids, monounsaturated - therapeutic use (65) 65
health aspects (64) 64
indoles - therapeutic use (63) 63
physiological aspects (63) 63
medicine (61) 61
liver - metabolism (60) 60
drugs (59) 59
liver (59) 59
dose-response relationship, drug (58) 58
aged (57) 57
plasma (55) 55
in-vitro (54) 54
proteins (54) 54
rats, sprague-dawley (54) 54
statins (53) 53
cancer (52) 52
metabolites (52) 52
nutrition (50) 50
rats, wistar (50) 50
fatty acids, monounsaturated - adverse effects (48) 48
time factors (48) 48
chemistry, multidisciplinary (47) 47
drug delivery systems (47) 47
biological availability (46) 46
fatty acids, monounsaturated (46) 46
indoles - adverse effects (46) 46
multidisciplinary sciences (46) 46
science (46) 46
triglycerides - blood (46) 46
fatty-acids (45) 45
kinetics (45) 45
lipid metabolism (44) 44
quaternary ammonium compounds - chemistry (44) 44
rodents (44) 44
tissue distribution (44) 44
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (43) 43
physiology (43) 43
cell line, tumor (42) 42
docosahexaenoic acid (42) 42
fatty acids - metabolism (42) 42
fatty acids, monounsaturated - blood (42) 42
liposomes (42) 42
pravastatin (42) 42
obesity (41) 41
risk factors (41) 41
administration, oral (40) 40
diabetes (40) 40
gene expression (40) 40
pharmacology (40) 40
pharmacy (40) 40
expression (39) 39
hypercholesterolemia - drug therapy (39) 39
indoles - administration & dosage (39) 39
triglycerides (39) 39
anticholesteremic agents - pharmacokinetics (38) 38
article (37) 37
bioavailability (37) 37
cross-over studies (37) 37
fatty acids, monounsaturated - metabolism (37) 37
in-vivo (37) 37
oleic acid (37) 37
permeability (36) 36
toxicology (36) 36
biochemistry (35) 35
cell line (35) 35
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (35) 35
lipids - chemistry (35) 35
dietary supplements (34) 34
pharmacology/toxicology (34) 34
simvastatin (34) 34
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (825) 825
Chinese (4) 4
French (3) 3
Spanish (2) 2
German (1) 1
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1308 - 1314
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic... 
RAT | SEVERE RHABDOMYOLYSIS | COMBINATION THERAPY | LIVER | PHARMACOLOGY & PHARMACY | CERIVASTATIN | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | ROSUVASTATIN | POLYPEPTIDE | FAMILY | Organic Anion Transporters, Sodium-Independent - genetics | Fatty Acids, Monounsaturated - pharmacology | Cricetulus | Hypolipidemic Agents - metabolism | Hypoglycemic Agents - metabolism | Taurocholic Acid - metabolism | Humans | Hepatocytes - metabolism | Simvastatin - pharmacology | Organic Anion Transporters - metabolism | Chromans - metabolism | Hepatocytes - cytology | Indoles - metabolism | Organic Anion Transporters - genetics | Drug Interactions | Anticholesteremic Agents - metabolism | Chromans - pharmacology | Fatty Acids, Monounsaturated - metabolism | Organic Anion Transporters, Sodium-Independent - metabolism | Indoles - pharmacology | Biological Transport - drug effects | Thiazolidinediones - pharmacology | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Pravastatin - pharmacology | Recombinant Proteins - metabolism | Taurocholic Acid - pharmacology | Cell Line | Cricetinae | Pravastatin - metabolism | Simvastatin - metabolism | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Thiazolidinediones - metabolism | Hypoglycemic Agents - pharmacology | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Protein Binding | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Kinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Anticholesteremic Agents - pharmacology | Gemfibrozil - metabolism
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 02/2016, Volume 13, Issue 2, pp. 557 - 567
The oral route of administration is still by far the most ubiquitous method of drug delivery. Development in this area still faces many challenges due to the... 
oral dosage | motility | migrating motor complex | mechanistic physiological model | gastric emptying | bioequivalence | clinical trial simulation | MEDICINE, RESEARCH & EXPERIMENTAL | BOWEL WATER-CONTENT | TRANSIT | HUMAN SMALL-INTESTINE | HEALTHY-SUBJECTS | PHASE-III | HUMANS | PHARMACEUTICAL DOSAGE FORMS | MODEL | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | ABSORPTION | Anticholesteremic Agents - blood | Fatty Acids, Monounsaturated - administration & dosage | Humans | Immunosuppressive Agents - pharmacokinetics | Intestinal Absorption - drug effects | Gastrointestinal Motility - drug effects | Male | Indoles - administration & dosage | Tissue Distribution | Fluorouracil - administration & dosage | Immunosuppressive Agents - blood | Fluorouracil - blood | Computer Simulation | Diethylcarbamazine - blood | Lipoxygenase Inhibitors - blood | Fatty Acids, Monounsaturated - blood | Immunosuppressive Agents - administration & dosage | Diethylcarbamazine - pharmacokinetics | Administration, Oral | Diethylcarbamazine - administration & dosage | Indoles - blood | Gastrointestinal Transit - drug effects | Lipoxygenase Inhibitors - administration & dosage | Anticholesteremic Agents - pharmacokinetics | Lipoxygenase Inhibitors - pharmacokinetics | Gastric Emptying - drug effects | Models, Biological | Anticholesteremic Agents - administration & dosage | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Fluorouracil - pharmacokinetics
Journal Article
CMAJ, ISSN 0820-3946, 02/2015, Volume 187, Issue 3, pp. 174 - 180
Background: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | OATP TRANSPORTERS | CONCOMITANT USE | DRUG-INTERACTIONS | OCT UPTAKE TRANSPORTERS | HEPATIC-UPTAKE | INHIBITORS | RHABDOMYOLYSIS | ROSUVASTATIN | DISPOSITION | Fluorobenzenes - pharmacokinetics | Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors | Humans | Male | Pyrimidines - metabolism | Indoles - metabolism | Drug Interactions | Fatty Acids, Monounsaturated - therapeutic use | Fluvastatin | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Fatty Acids, Monounsaturated - metabolism | Aged, 80 and over | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Pravastatin - therapeutic use | Solute Carrier Organic Anion Transporter Family Member 1B3 | Fluorobenzenes - metabolism | Clarithromycin - adverse effects | Pravastatin - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Organic Anion Transporters | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Hyperkalemia - chemically induced | Pyrimidines - pharmacokinetics | Rhabdomyolysis - chemically induced | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Liver-Specific Organic Anion Transporter 1 | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Fluorobenzenes - therapeutic use | Pravastatin - pharmacokinetics | Complications and side effects | Clarithromycin | Pravastatin | Biopolymers | Cytochrome P-450 | Antilipemic agents | Prescription drugs | Side effects | Older people | Risk factors | Statins | Index Medicus | Abridged Index Medicus | Research
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 12/2018, Volume 125, pp. 11 - 22
Drug-fortified cationic liposomes of 6‑methoxy‑2‑naphthylacetic acid (6‑MNA) were prepared and characterized by various techniques. The residence time of... 
Arthritis | Non-steroidal anti-inflammatory drugs (NSAIDs) | Liposomes | 6‑Methoxy‑2‑naphthylacetic acid (6‑MNA) | Intra-articular (IA) delivery | INTRAARTICULAR INJECTION | SYNOVIAL-FLUID | FATE | DELIVERY | CARTILAGE | RABBITS | PAIN | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | 6-Methoxy-2-naphthylacetic acid (6-MNA) | NIH 3T3 Cells | Arthritis, Experimental - drug therapy | Fatty Acids, Monounsaturated - administration & dosage | Phosphatidylcholines - administration & dosage | Male | Naphthaleneacetic Acids - administration & dosage | Arthritis, Experimental - metabolism | Delayed-Action Preparations - administration & dosage | Arthritis, Experimental - pathology | Phosphatidylcholines - pharmacokinetics | Delayed-Action Preparations - pharmacokinetics | Phosphatidylethanolamines - pharmacokinetics | Naphthaleneacetic Acids - pharmacokinetics | Cell Survival - drug effects | Phosphatidylethanolamines - administration & dosage | Rats, Sprague-Dawley | Cartilage, Articular - pathology | Animals | Quaternary Ammonium Compounds - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Fatty Acids, Monounsaturated - pharmacokinetics | Mice | Quaternary Ammonium Compounds - pharmacokinetics | Cartilage, Articular - drug effects | Thin films | C-reactive protein | Medical examination | Analysis | Models | Dielectric films | Nonsteroidal anti-inflammatory drugs | Drug therapy | Blood
Journal Article
Molecular Nutrition & Food Research, ISSN 1613-4125, 10/2018, Volume 62, Issue 20, pp. e1800322 - n/a
The endothelial cell becomes “activated” by fatty acid (palmitate) stimulation of the NFκB pathway, synthesizing cytokines (monocyte chemotactic protein‐1,... 
palmitoleic acid | cytokines | EAHy926 cells | inflammation | TNF‐α | endothelial dysfunction | TNF-α | PPAR-ALPHA | APOPTOSIS | ACTIVATION | TNF-alpha | FOOD SCIENCE & TECHNOLOGY | FATTY-ACIDS | MECHANISMS | VCAM-1 | GENE | NF-KAPPA-B | EXPRESSION | Human Umbilical Vein Endothelial Cells | Tumor Necrosis Factor-alpha - metabolism | Fatty Acids, Monounsaturated - pharmacology | Humans | Tumor Necrosis Factor-alpha - genetics | Palmitic Acids - pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Inflammation - metabolism | Oleic Acid - pharmacology | Inflammation - drug therapy | Chemokine CCL2 - metabolism | Chemokine CCL5 - metabolism | Oleic Acid - pharmacokinetics | Palmitic Acids - pharmacology | Interleukin-6 - metabolism | Cell Line | Cell Survival - drug effects | Interleukin-6 - genetics | Gene Expression Regulation | Chemokine CCL2 - genetics | Intercellular Adhesion Molecule-1 - metabolism | Chemokine CCL5 - genetics | Inflammation - genetics | Fatty Acids, Monounsaturated - pharmacokinetics | Endothelial Cells - drug effects | Monounsaturated fatty acids | Anti-inflammatory drugs | Inflammation | Comparative analysis | Gene expression | Saturated fatty acids | Endothelium | Atherogenesis | Genes | Arachidonic acid | Palmitic acid | Fatty acids | Endothelial cells | Prostaglandin endoperoxide synthase | Proteins | Monocytes | Palmitoleic acid | Oleic acid | Tumor necrosis factor | Cell adhesion | Tumor necrosis factor-TNF | Peroxisome proliferator-activated receptors
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 11/2018, Volume 81, pp. 195 - 207
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 05/2015, Volume 32, Issue 5, pp. 1634 - 1647
To evaluate whether the impact of functional modulation of the breast cancer resistance protein (BCRP, ABCG2 421C > A) on human pharmacokinetics after oral... 
BCRP | Gastrointestinal absorption | ABCG2 421C>A | Cynomolgus monkey | Knockout mouse | QUALITATIVE EVALUATION | DRUG-INTERACTIONS | BINDING CASSETTE TRANSPORTERS | GENE POLYMORPHISMS | CHEMISTRY, MULTIDISCIPLINARY | ABCG2 BCRP | SULFASALAZINE | ABCG2 421C > A | PHARMACOLOGY & PHARMACY | CYNOMOLGUS MONKEYS | IN-VIVO PROBE | CACO-2 CELLS | C421A POLYMORPHISM | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Quinolines - blood | Area Under Curve | Fatty Acids, Monounsaturated - administration & dosage | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Intestinal Absorption - drug effects | Macaca fascicularis | Male | Quinolines - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Rosuvastatin Calcium - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfasalazine - pharmacokinetics | ATP-Binding Cassette Transporters - genetics | Sulfasalazine - blood | ATP-Binding Cassette Transporters - metabolism | Fatty Acids, Monounsaturated - blood | Female | Rosuvastatin Calcium - blood | Caco-2 Cells | Tetrahydroisoquinolines - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Indoles - blood | Mice, Knockout | Sulfasalazine - administration & dosage | Animals | Acridines - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | ATP-Binding Cassette Transporters - antagonists & inhibitors | Sulfasalazine | Breast cancer | Proteins | Pharmacology | Kinetics | Drug resistance | Monkeys & apes | Substrates
Journal Article
Journal Article
Transplantation, ISSN 0041-1337, 06/2014, Volume 97, Issue 12, pp. 1266 - 1271
BACKGROUNDDyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR... 
Renal transplantation | Lipid lowering | Rosuvastatin | Drug-drug interaction | Everolimus | Pharmacokinetic | SURGERY | MANAGEMENT | IMMUNOLOGY | ATORVASTATIN | TRANSPLANTATION | GLOMERULAR-FILTRATION-RATE | IN-VITRO | PHARMACOKINETICS | DISEASE | HEALTHY-VOLUNTEERS | DYSLIPIDEMIA | INHIBITORS | CYCLOSPORINE | Fluorobenzenes - pharmacokinetics | Prospective Studies | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Drug Interactions | Fatty Acids, Monounsaturated - therapeutic use | Cytochrome P-450 CYP3A - genetics | Fatty Acids, Monounsaturated - adverse effects | Lipids - blood | Female | Dyslipidemias - etiology | Sirolimus - adverse effects | Dyslipidemias - drug therapy | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Rosuvastatin Calcium | Genotype | Treatment Outcome | Sirolimus - pharmacokinetics | Biomarkers - blood | Sulfonamides - pharmacokinetics | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Cytochrome P-450 CYP3A - metabolism | Norway | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Fatty Acids, Monounsaturated - pharmacokinetics | Immunosuppressive Agents - adverse effects | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Fluorobenzenes - adverse effects | Drug Substitution | Fluorobenzenes - therapeutic use | Kidney Transplantation - adverse effects
Journal Article
Journal Article